120 related articles for article (PubMed ID: 38691920)
1. Comprehensive quantifications of tumour microenvironment to predict the responsiveness to immunotherapy and prognosis for paediatric neuroblastomas.
Song M; Sun Y; Hu Y; Wang C; Jin Y; Liu Y; Da Y; Zhao Q; Zheng R; Li L
Int Immunopharmacol; 2024 May; 133():112145. PubMed ID: 38691920
[TBL] [Abstract][Full Text] [Related]
2. Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients.
Luo B; Wang L; Gao W; Su Y; Lu Y; Zheng J; Yin J; Zhao Q; Li J; Da Y; Li L
Front Immunol; 2022; 13():845757. PubMed ID: 35401536
[TBL] [Abstract][Full Text] [Related]
3. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
[TBL] [Abstract][Full Text] [Related]
4. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
[TBL] [Abstract][Full Text] [Related]
5. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
6. Verification of genetic differences and immune cell infiltration subtypes in the neuroblastoma tumour microenvironment during immunotherapy.
Qian B; Sun J; Zuo P; Da M; Mo X; Fang Y
World J Surg Oncol; 2022 May; 20(1):169. PubMed ID: 35643506
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
8. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Bao R; Spranger S; Hernandez K; Zha Y; Pytel P; Luke JJ; Gajewski TF; Volchenboum SL; Cohn SL; Desai AV
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272305
[TBL] [Abstract][Full Text] [Related]
9. A novel ganglioside-related risk signature can reveal the distinct immune landscape of neuroblastoma and predict the immunotherapeutic response.
Yang J; Han L; Sha Y; Jin Y; Li Z; Gong B; Li J; Liu Y; Wang Y; Zhao Q
Front Immunol; 2022; 13():1061814. PubMed ID: 36605200
[TBL] [Abstract][Full Text] [Related]
10. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
11. A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.
Tian XM; Xiang B; Yu YH; Li Q; Zhang ZX; Zhanghuang C; Jin LM; Wang JK; Mi T; Chen ML; Liu F; Wei GH
Front Immunol; 2022; 13():999849. PubMed ID: 36211401
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of pyroptotic gene prognostic signatures associated with tumor immune microenvironment and genomic mutation in breast cancer.
Zhang H; Yu X; Yang J; He G; Zhang X; Wu X; Shen L; Zhou Y; Cheng X; Liu X; Zhu Y
Front Immunol; 2022; 13():933779. PubMed ID: 36090993
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer-Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms.
Neviani P; Wise PM; Murtadha M; Liu CW; Wu CH; Jong AY; Seeger RC; Fabbri M
Cancer Res; 2019 Mar; 79(6):1151-1164. PubMed ID: 30541743
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
15. Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition.
Bianchi G; Morandi F; Cilli M; Daga A; Bocelli-Tyndall C; Gambini C; Pistoia V; Raffaghello L
PLoS One; 2012; 7(10):e48654. PubMed ID: 23119082
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
17. Model for predicting prognosis and immunotherapy based on CD
Bao W; Song Z; Wan H; Yu X; Chen Z; Jiang Y; Chen X; Le K
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9839-9855. PubMed ID: 37248319
[TBL] [Abstract][Full Text] [Related]
18. Immune characterization of pre-clinical murine models of neuroblastoma.
Webb ER; Lanati S; Wareham C; Easton A; Dunn SN; Inzhelevskaya T; Sadler FM; James S; Ashton-Key M; Cragg MS; Beers SA; Gray JC
Sci Rep; 2020 Oct; 10(1):16695. PubMed ID: 33028899
[TBL] [Abstract][Full Text] [Related]
19. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
20. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
